tradingkey.logo

Grail Inc

GRAL
100.070USD
+6.010+6.39%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
3.62BValor de mercado
PerdaP/L TTM

Mais detalhes de Grail Inc Empresa

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Informações de Grail Inc

Código da empresaGRAL
Nome da EmpresaGrail Inc
Data de listagemJun 12, 2024
CEORagusa (Robert)
Número de funcionários1000
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
Endereço1525 O'brien Drive
CidadeMENLO PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94025
Telefone18336942553
Sitehttps://grail.com/
Código da empresaGRAL
Data de listagemJun 12, 2024
CEORagusa (Robert)

Executivos da empresa Grail Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
68.19K
+6082.00%
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
48.29K
-25000.00%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
12.65K
+329.00%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
10.33K
+213.00%
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
Por EmpresaUSD
Nome
Receita
Proporção
Screening
32.81M
90.64%
Development Services
3.39M
9.36%
Por RegiãoUSD
Nome
Receita
Proporção
United States
32.65M
90.20%
International
3.55M
9.80%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Screening
32.81M
90.64%
Development Services
3.39M
9.36%

Distribuição de ações

Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
Outro
70.71%
Investidores
Investidores
Proporção
Illumina Inc
8.98%
BlackRock Institutional Trust Company, N.A.
5.45%
PRIMECAP Management Company
5.18%
The Vanguard Group, Inc.
5.06%
CRCM L.P.
4.62%
Outro
70.71%
Tipos de investidores
Investidores
Proporção
Investment Advisor
26.31%
Investment Advisor/Hedge Fund
21.22%
Hedge Fund
13.43%
Corporation
8.98%
Research Firm
4.26%
Individual Investor
1.06%
Bank and Trust
0.38%
Venture Capital
0.38%
Pension Fund
0.27%
Outro
23.71%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
989
25.81M
66.22%
-6.45M
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Illumina Inc
3.50M
8.98%
-1.00M
-22.21%
Nov 17, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
5.45%
+37.64K
+1.81%
Sep 30, 2025
PRIMECAP Management Company
2.02M
5.18%
-33.35K
-1.62%
Sep 30, 2025
The Vanguard Group, Inc.
1.81M
4.64%
-85.37K
-4.50%
Sep 30, 2025
CRCM L.P.
1.80M
4.62%
-42.00K
-2.28%
Oct 06, 2025
Baker Bros. Advisors LP
1.63M
4.18%
--
--
Sep 30, 2025
Farallon Capital Management, L.L.C.
1.61M
4.13%
+232.00K
+16.85%
Nov 17, 2025
State Street Investment Management (US)
1.32M
3.38%
+69.55K
+5.58%
Sep 30, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.66%
-2.00K
-0.19%
Sep 30, 2025
Sessa Capital
786.14K
2.02%
--
--
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
Ver Mais
ROBO Global Healthcare Technology & Innovation ETF
Proporção3.75%
Clough Select Equity ETF
Proporção2.7%
Clough Hedged Equity ETF
Proporção2.53%
Franklin Genomic Advancements ETF
Proporção2.49%
First Trust Small Cap Growth AlphaDEX Fund
Proporção1.08%
State Street SPDR S&P Biotech ETF
Proporção0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.59%
ProShares Ultra Nasdaq Biotechnology
Proporção0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.42%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI